7-deoxynarciclasine

structure in first source

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

1.	Hepatocellular Carcinoma (Hepatoma) 12/15/2019 - "In our study, we have identified that 7-deoxynarciclasine (7-DONCS) is a potential inhibitor of Akt, which results in the repression of multiple oncogenic processes in hepatocellular carcinoma (HCC). " 12/15/2019 - "7-Deoxynarciclasine shows promising antitumor efficacy by targeting Akt against hepatocellular carcinoma."
2.	Neoplasms (Cancer) 01/01/2006 - "Against the murine P388 lymphocytic leukemia and a panel of human cancer cell lines, the parent natural products, 7-deoxynarciclasine (2b) and 7-deoxy-trans-dihydronarciclasine (3a), were found to generally be more cancer cell growth inhibitory (GI50 0.1 to <0.01 microg/mL) than the compounds with structural modifications such as amine 8 by a factor of 10 or more. "
3.	Lymphoid Leukemia 01/01/2006 - "Against the murine P388 lymphocytic leukemia and a panel of human cancer cell lines, the parent natural products, 7-deoxynarciclasine (2b) and 7-deoxy-trans-dihydronarciclasine (3a), were found to generally be more cancer cell growth inhibitory (GI50 0.1 to <0.01 microg/mL) than the compounds with structural modifications such as amine 8 by a factor of 10 or more. "
4.	Infections 12/01/2001 - "In vitro activities of two antimitotic compounds, pancratistatin and 7-deoxynarciclasine, against Encephalitozoon intestinalis, a microsporidium causing infections in humans."

1.	Antimitotic Agents
2.	Amines
3.	7-deoxy-trans-dihydronarciclasine
4.	pancratistatin
5.	A-factor (Streptomyces)